We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Invltd Nm | LSE:2005 | London | Ordinary Share | ZAE000081949 | INVESTEC LTD NM |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | ZAC |
Invltd Nm (2005) Share Charts1 Year Invltd Nm Chart |
|
1 Month Invltd Nm Chart |
Intraday Invltd Nm Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 28/3/2009 | 17:33 | Perfect Storm is Coming: in 2005 Maybe | 167 |
| 20/7/2005 | 12:09 | 2005 The Year of the Biotech? | 74 |
| 07/1/2005 | 13:46 | 2005 - the shares to watch | 14 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 06/9/2005 22:06 by topbidd The perfect stormSep 6th 2005 From The Economist Global Agenda It's not just natural disasters that need preparing for: |
Posted at 28/4/2005 01:31 by mr ashley james Perfect Storm is Coming: in 2005 Maybe For the British and other European Monarchies quite clearly. Remember Mussolini? |
Posted at 30/1/2005 07:42 by mjneish Fickena, here's what a quick foray into Pharmagene has turned up; I've kept it as concise as possible. By all means exclude it from the header if it's too early-stage.Pharmagene [PGN] Web page: Development strategy: to achieve early-stage licensing and development partners for their therapeutic candidates. Discussions are underway for their four leading compounds. 2005 R1 for irritable bowel syndrome: entered Phase I in January 2005 R4 for migraine: to enter Phase I R65 for women's health, glaucoma and immunology: to enter pre-clinical trials R99 for inflammatory/immune disorders: pre-clinical candidate to be selected Pharmagene also has a drug discovery services division that is generating revenues. The share price is currently (end of January 2005) trading around cash level. |
Posted at 13/1/2005 13:47 by daimon Hello Fickena, I did some more digging regarding expected 2005 newsflow for Phytopharm and apart from the expected interim and final year figures which should show the progress of the ongoing sales of the two canine products, I discovered the following information from Phytopharm's website. I've pasted what should be the address for each particular page at the end of each section. Thanks for setting up this thread, it is very useful to collate so much relevant information in one readily avaialble and readable source. PYM 2005 expected info? Cogane Alzheimer's treatment. Mode of action In pre-clinical studies, the synthetic chemical Cogane, has been shown to be neuroprotective against beta-amyloid and glutamate damage, to reverse the decrease of neuronal growth factors and to reverse neuronal degeneration observed in the ageing brain. Importantly, this product restores levels of proteins that are altered in the ageing brain, returning them to levels observed in the young and causing beneficial neurite outgrowth and branching. In addition, Cogane restores the learning and memory ability in Alzheimer's disease models and thereby offers the potential to reverse the symptoms of Alzheimer's disease Progress to date The first clinical trial was conducted using a semi purified crude extract. The key findings showed that the 30 patients treated over the 3-month trial significantly improved their mini-mental state estimate (MMSE) score. The first phase I trial using Cogane investigated the safety, tolerability and pharmacokinetics in healthy volunteers. The second phase I trail examined repeat doses to healthy elderly volunteers for 7 days followed immediately by a 28-day trial. In November 2003 Phytopharm reported the successful completion of this study demonstrating that Cogane has absorption and pharmacokinetic characteristics suitable for once daily dosing and is well tolerated with a good emergent safety profile. In December 2003, we announced that we had been granted clearance by the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a phase II 'proof of principle' clinical study in Alzheimer's disease patients under a clinical trial exemption (CTX) certificate. The study utilises a randomised, double blind placebo-controlled design to evaluate the safety, efficacy and pharmacokinetic profile of Cogane after once daily oral administration over 3 months. The effects of Cogane on memory, concentration and executive function will be evaluated during the study. The study is expected to report in H2 2005 Asthma and other inflammatory diseases. Preclinical stage Programme: P61 Asthma is a chronic inflammatory disorder of the airways. Approximately 8 million people in the UK have been diagnosed with asthma, and the condition costs the NHS on average £850 million per year (Source: Asthma UK). Asthma causes recurrent episodes of wheezing, breathlessness, chest tightness and cough. In addition, asthma is usually associated with widespread but variable airflow obstruction. Inhibition of inflammation and relaxation of airway smooth muscle are therefore key components of asthma treatment. Mode of action A number of lead compounds have been synthesised, demonstrating anti-inflammatory and anti-spasmodic activity in several established models of asthma and inflammation. Progress to date The mechanism of action and structure activity relationships are being developed and patented. We anticipate the lead candidate ready for development within 2005. |
Posted at 12/1/2005 14:48 by s h b fickenaYes CBF is a UK listed Biopharma manufacturer, is a good recovery play for 2005. also you might like to check out this comprehensive report for whats in store for Biotech in 2005. December 22, 2004 Burrill's Biotech Outlook for 2005 |
Posted at 10/1/2005 17:03 by fickena Fidra,Dodgy Company! I tried to email them and their investor relation address is investor.relations@a However they do not even own the domain akers.com, some family in San Fransisco does! The mail bounced. Their site is over a year out of date and every announcement they seem to make is followed up by a correction, issued the wrong amount of shares and even published another companies trading update instead of their own. Plus the company's share price has been plumenting, all the while the directors are issuing themselves shares! Will wait and see with this one. |
Posted at 09/1/2005 22:00 by qazwsx123 Fickena (Post 29) my comment about the revised timetable for a deal on OXB's Trovax represents the latest know news and was published this Friday 7/1/2005 in Investors Chronicle (p28); a known third party. As such, your information for OXB's Trovax (quote "commercial collaboration") is misleading without it. You need to keep the information up to date, otherwise it will be useless. Obviously, if a Company gives an interview (as apparently, in the case of OXB regarding Trovax) in which they disclose new information about potential timetabling or trial funding, it is important to include such information. The key thing is to mention a reference, then people can decide for themselves. .................... Investors Chronicle 7th January 2005 (p28): Oxford Biomedica: Trovax: "...the drug has not yet found a partner and Oxford Biomedica is considering funding a Phase III trial itself". .................... As such, one might conclude the following: 1) OXB may fund lead Trovax PIII's themselves, so a deal for Trovax still appears be some years away. 2) If OXB fund PIII Trovax themselves, it would seem logical for them to stage a share issue soon in order to raise cash to fund the trials. 3) An earlier deal would probably not provide the kind of terms which OXB seek, i.e. would be comparatively small. |
Posted at 09/1/2005 20:00 by supercity nice thread.....even if it is not added i am sure that gwpharmaceuticals (gwp)should get a mention...could be an absolute goldmine later in the year...i do hold....too much to post what it is all about but in short the main product at present is Sativex (a cannabis based medicine that helps MS sufferers amoung others). Uk approval delayed six months (coincidentally after the election) but Canada have issued a Qualifying Notice for the approval of Sativex. check out the website, the pull back in share price on the uk disappointment may well provide a good buying opportunity. |
Posted at 08/1/2005 11:54 by fickena Mj,I was thinking along the same lines. I think the title will soon be obsolete as well, so I was thinking something along the lines of "Biotech Targets for 2005" or "Biotech Targets and Milestones for 2005" etc So once it gets going then I will start a new thread and copy all the progress tables across. It regards to the logos I also agree, just wanted to give it some wow factor to start with to gain interest and then hopefully I would like to include a small 2005 chart be the side of each company to help show the link (or not) of expected news flow, news and price changes. I need some more input though. I have someone working on MLB info, but I thought the OXB lot would be clambering to get theirs up, but nothing yet. There is a least 100 biotechs around, so I am surprised I haven't had more suggested yet. |
Posted at 07/1/2005 10:16 by bluemango I imagine this thread could rapidly grow into having a list of almost all UK biotechs, nevertheless I consider Proteome Sciences (PRM) certainly deserves a mention. Low cash-burn, concentration on diagnostics (therefore without expensive drug trials and lengthy approvals process) and with patented claims to be able to diagnose (by protein analysis of blood samples), amongst others, vCJD in blood donations, BSE in live cattle, stroke, solid organ transplant rejection, and various forms of cancer. Share price is at an historic low due to disappointments/dela Website: As well as their diagnostic 'biomarkers', the company also offer leading-edge proteomics expertise, with applications including drug refurbishment, toxioproteomics (predicting toxicity of new drug candidates), prognostics and discovery of new therapeutics. Proteome Sciences also hold a 40% stake in US subsidiary Intronn which is developing novel gene therapy techniques including potential for cancer imaging and therapeutics for genetic diseases such as cystic fibrosis. The company is headed by CEO Chris Pearce, ex-Merchant Banker and head of previous successful business Fitness First. Aim-listed Proteome Sciences is my personal target for highest-growing UK biotech for 2005. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
